Bristol-Myers Squibb Co. will stop making and selling Tequin, the antibiotic linked to serious blood-sugar complications.

According to spokesman Eric Miller, Bristol-Myers Squibb will return rights to the drug to Kyorin Pharmaceutical Company in Japan

A Canadian study urges doctors to stop prescribing the Bristol Myers Squibb antibiotic, Tequin, saying it can have "life threatening" side effects, including diabetes.

Elderly people who took the medication were 17 times more likely to develop serious diabetes than if they took a different antibiotic, and were four times more likely to be hospitalized for low blood sugar

Bristol-Myers Squibb Co. announced on Thursday that it has changed the labeling for Tequin (gatifloxacin), an antibiotic used to treat pneumonia, bronchitis, uncomplicated gonorrhea, and infections such as urinary tract, kidneys, and skin.

The U.S. Food and Drug Administration (FDA) says the labeling changes update the prescription information as a result of continued reports of serious cases of hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) in patients receiving Tequin